ACAD
ACAD clinical trials: ACADIA PHARMACEUTICALS INC
Every trial on ClinicalTrials.gov where ACADIA PHARMACEUTICALS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 50
- Trials linked
- 41
- As lead sponsor
- 9
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ACAD on the catalyst calendar · ACAD registry changes
- Primary completion Aug 2027Sponsor estimatePhase 2NCT07284667ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant ResponseACADIA Pharmaceuticals Inc. · Major Depressive Disorder (MDD)RecruitingACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 2/Phase 3NCT06159673ACP-204 in Adults With Alzheimer's Disease PsychosisACADIA Pharmaceuticals Inc. · Alzheimer's Disease PsychosisRecruitingACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2029Sponsor estimatePhase 3NCT07095465Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia PsychosisACADIA Pharmaceuticals Inc. · Lewy Body Dementia PsychosisRecruitingACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2028Sponsor estimatePhase 2NCT07029581Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia PsychosisACADIA Pharmaceuticals Inc. · Lewy Body Dementia PsychosisRecruitingACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2029Sponsor estimatePhase 3NCT06194799ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension StudyACADIA Pharmaceuticals Inc. · Alzheimer's Disease PsychosisEnrolling by invitationACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 19, 2025ActualPhase 3NCT06173531Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeACADIA Pharmaceuticals Inc. · Hyperphagia in Prader-Willi SyndromeCompletedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 19, 2025ActualPhase 3NCT06420297OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeACADIA Pharmaceuticals Inc. · Hyperphagia in Prader-Willi SyndromeTerminatedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 14, 2025ActualPhase 2/Phase 3NCT05555615Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum DisorderACADIA Pharmaceuticals Inc. · Irritability Associated With Autism Spectrum DisorderTerminatedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 27, 2024ActualPhase 2/Phase 3NCT05523895Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum DisorderACADIA Pharmaceuticals Inc. · Irritability Associated With Autism Spectrum DisorderCompletedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 25, 2024ActualPhase 3NCT04531982Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of SchizophreniaACADIA Pharmaceuticals Inc. · SchizophreniaCompletedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2024ActualPhase 3NCT03121586Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaACADIA Pharmaceuticals Inc. · SchizophreniaTerminatedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2008ActualPhase 2NCT00490516ACP-104 in Acutely Psychotic Subjects With SchizophreniaACADIA Pharmaceuticals Inc. · SchizophreniaCompletedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 6, 2022ActualPhase 2NCT05008835Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the KneeACADIA Pharmaceuticals Inc. · Osteoarthritis PainTerminatedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 26, 2022ActualPhase 4NCT04292223Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease PsychosisACADIA Pharmaceuticals Inc. · Parkinson Disease PsychosisCompletedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 5, 2023ActualPhase 3NCT03623321Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseACADIA Pharmaceuticals Inc. · Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseCompletedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 6, 2022ActualPhase 3NCT03575052A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseACADIA Pharmaceuticals Inc. · Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseCompletedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2023ActualPhase 3NCT04776746Open-Label Extension Study of Trofinetide for Rett SyndromeACADIA Pharmaceuticals Inc. · Rett SyndromeTerminatedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2023ActualPhase 2/Phase 3NCT04988867An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett SyndromeACADIA Pharmaceuticals Inc. · Rett SyndromeTerminatedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 28, 2021ActualPhase 3NCT04181723Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)ACADIA Pharmaceuticals Inc. · Rett SyndromeCompletedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 19, 2022ActualPhase 3NCT04279314Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett SyndromeACADIA Pharmaceuticals Inc. · Rett SyndromeCompletedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 11, 2022ActualPhase 2NCT04855240Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following BunionectomyACADIA Pharmaceuticals Inc. · Acute Postoperative PainCompletedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 22, 2021ActualPhase 3NCT04000009Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentACADIA Pharmaceuticals Inc. · Adjunctive Treatment of Major Depressive DisorderTerminatedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2020ActualPhase 3NCT03968159Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentACADIA Pharmaceuticals Inc. · Adjunctive Treatment of Major Depressive DisorderCompletedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 25, 2020ActualPhase 2NCT04164758Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With...ACADIA Pharmaceuticals Inc. · Parkinson's DiseaseTerminatedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 8, 2021ActualNo phase registeredNCT03152292The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) StudyACADIA Pharmaceuticals Inc. · Parkinson Disease PsychosisTerminatedACADLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 25 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner